Immunotherapy has the potential to treat almost any type of cancer. Learn how we are making this a reality for more patients sooner.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
Have a creative idea for a fundraiser you'd like to host to benefit cancer research? Or are you seeking ideas for how you can help us achieve our mission to conquer all cancers? Get inspired by our ideas and tips.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can derail progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, keeping promising new immunotherapies on the fast track to patients.
Cancer patients are now beginning to benefit from advances in cancer immunotherapy. Watch this story of hope and survival, and be inspired to help us conquer cancer.
Browse our directory of scientific leaders who volunteer their time and expertise to help ensure that we fund the most innovative and promising research possible.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
September 10, 2013
Jill O'Donnell-Tormey, Ph.D.
Combining multiple treatments given at the right time and in the right doses is key to optimizing cancer therapy, scientists believe.
clinical accelerator, clinical trial, collaboration, immunotherapy, ludwig institute, pancreatic cancer, ralph steinman, vaccine
Lloyd J. Old, the Father of Modern Tumor Immunology and the founding scientific and medical director of the Cancer Research Institute, succumbed to prostate cancer at the age of 78.
lloyd old, obituary
Whether a patient benefits from a cancer therapy can depend on existing genetic and other conditions within the patient and his or her tumors. Personalized approaches to cancer patient care will help ensure patients receive only those treatments that may benefit them rather than endure hit or miss rounds of potentially debilitating therapy.
herceptin, patient care, personalized medicine, side effects
The Forbes article reports how cancer immunotherapy is producing stories of seemlingly miraculous recovery in cancer patients. CRI has been there all along the way, ushering in the future of immune-based cancer treatments.
cancer miracles, immunotherapy, melanoma, skin cancer